Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 LC Sciences ... technologies, announced today that it is seeking beta ... innovative multiplex PCR based targeted sequencing technology. The ... analysis, that enables accurate detection of rare variants. ... Omega-Primer™ technologies. The company will collaborate with beta ...
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... Miami, FL (PRWEB) April 16, 2015 ... therapy cap distribution and physician network in Europe ... marketing company has appointed Fernando Bermúdez, former Business ... Director. , An industry veteran, Mr. Bermúdez’s professional ... by 75% in Spain, while also penetrating the ...
(Date:4/16/2015)... April 16, 2015 Regis Technologies looks ... Association for Cancer Research (AACR) annual meeting. Regis will ... Center, starting Saturday, April 18, in Philadelphia and running ... to title of the oldest and largest organization focused ... and grants, and partners with survivors to promote awareness ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Regis Technologies Joins American Association for Cancer Research Annual Meeting 2
... Oct. 7, 2011 Novelda AS announced today two new antennas ... antenna design is based on a Sinuous Antenna geometry. The antenna ... The upper PCB is the antenna itself; the lower PCB is ... about 70 degrees. This can be lowered by attaching a lens. ...
... AlloSource, ( www.allosource.org ) a leading ... for use in surgical procedures around the world, is ... Denver Business Journal,s inaugural awards program. With ... diminishing employee benefits, the Denver Business Journal ...
... Oct. 6, 2011 ProteinSimple today announced the ... quality control monitoring of protein-based therapeutics. The iCE3 ... 2011 conference, October 9-13, 2011, at Amelia Island, ... monitor product purity closely. Imaged capillary electrophoresis (iCE) ...
Cached Biology Technology:Wideband Antenna for Novelda Nanoscale Impulse Radar 2AlloSource Named One of Denver's Healthiest Employers 2AlloSource Named One of Denver's Healthiest Employers 3ProteinSimple Launches New System for Protein Biologics 2
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... DNA (mtDNA) has been used to establish migration and ... before Christopher Columbus sailed to the Americas. New research ... Genetics has used more detailed DNA analysis of ... and burial traditions of ancient Peru. The social ...
... 22, 2012 Frida Kahlo,s many haunting self-portraits have been ... have sold for millions of dollars at auction. Yet, despite ... failed reproduction attempts, relatively little attention has been paid to ... messages manifested in Kahlo,s work and surprised by the apparent ...
... pan-European study published in Science shows that mountain ... often results in raised species numbers on mountain tops, when ... This study, however, also shows that upward shifts can lead ... on detailed surveys of 66 mountain summits distributed between the ...
Cached Biology News:Forensic science used to determine who's who in pre-Columbian Peru 2A new diagnosis for Frida Kahlo's infertility 2A new diagnosis for Frida Kahlo's infertility 3A new diagnosis for Frida Kahlo's infertility 4Accelerating climate change exerts strong pressure on Europe's mountain flora 2
... Fixed clamp trays ... easy Magnetic drive ... rpm 25 mm amplitude ... 25 ml to 2000 ml, including ...
... fluorescent microscopy-based imaging system that accurately counts ... calculates cell viability, in a single test. ... variability associated with the subjective interpretation of ... EasyCount ViaSure Kit, up to six tests ...
... blotting. Get results sooner and save hours of ... Eliminates the need for a membrane transfer step ... are ready-to-use. No reagents to prepare or mix ... required. Guarantees a simple to perform, mistake-free detection ...
... CHEF-DR III variable angle system, 220-240 V, is ... 6 Mb DNA fragments by pulsed field gel ... power module, variable-speed pump, 14 x 13 cm ... 15-well, 1.5 mm thick comb, screened cap, disposable ...
Biology Products: